The role of neoadjuvant (NAD) chemotherapy (CHT) in patients with locally advanced gastric cancer (LAGC) is validated. However, some important limitations emerged from the literature, including patient selection, quality of surgery, and pathologic response evaluation. Neoadjuvant CHT for LAGC has been evaluated with a focus on safety and efficacy of the preoperative approach in terms of patient compliance, surgical outcomes, and pathologic response.
|Data di pubblicazione:||2015|
|Titolo:||Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients|
|Digital Object Identifier (DOI):||10.5301/tj.5000340|
|Codice identificativo ISI:||WOS:000366493000013|
|Codice identificativo Scopus:||2-s2.0-84955664272|
|Codice identificativo Pubmed:||25908036|
|Appare nelle tipologie:||Articolo su Rivista|